

# User manual for ESC 0-1 Hour Algorithm

Version 1, February 2023, in English



# 1. The Evidencio platform

The Evidencio platform facilitates the creation, use, validation and implementation of medical prediction models and clinical decision support tools. This user manual specifically relates to the ESC 0-1 Hour Algorithm. The User Manual can also be referred to as the Instructions For Use (IFU).

Throughout this manual CE-marked content and the term medical device are used interchangeably.

## 2. Disclaimer

Evidencio provides information, models, calculators, equations, and algorithms (tools) intended for use by healthcare professionals. Some of these tools have been certified as CE-medical devices. For such CE-marked content the 'Official Legal Disclaimer for CE-marked content' applies. All other content and tools provided by Evidencio are explicitly only covered by the 'Official Legal Disclaimer for non CE-marked content' both are available here: <a href="https://www.evidencio.com/disclaimer">https://www.evidencio.com/disclaimer</a>

# 3. Warnings



#### 1. Warnings for CE-marked content

Calculations alone should never dictate patient care, and are no substitute for professional judgement. This tool is only to be used by physicians in a clinical setting, and is not for patient use.

Always read the intended use before using this tool.

Before reading the result, double check the filled in values to prevent errors.

Results that concern risk percentages, do not guarantee certain outcomes. When there is a risk present, do not expect an event to not occur at all, even if the risk is very small.

This model is only intended for use in settings where the usage and result of a model are never immediately needed.



# 4. Model landing page

The medical device model on the Evidencio platform is shown in Figure 1. The model landing page contains the following sections, that are indicated in Figure 1.

	onin i (ns-cīnī) 0	-hour/1-hour algorithm	(MDK) ♥	Details
he high consitivity and as to	oin T (be etet) 0 beauti	hour algorithm		■ Intended use
he high-sensitivity cardiac tropon is-cTnT blood concentration at pro		- T		■ Electronic label ◆
tratify patients suspected of acut				Release Notes
				■ User manual
tesearch authors: Reichlin T, Schindler C				
., Moehring B, Ziller R, Hoeller R, Gimene reese M, Stelzig C, Freidank H, Osswald		ldi K, Balmelli C,		
Draft   Cardiology   Custom mode	d		****	
State   Cardiology   Caston mode			***	
LOT V-1.1-3448.23.02.20 <b>( (</b>				
2797 UDI (01)08719327522776(8012)v1.1(	4326)230220(240)3448			
Download the User manual for	Medical device prediction m	odels and consult the Intended us	e.	
ns-cTnT level at 0h	0	>	ng/L	Absolute change of
s-cTnT level at presentation to the mergency department.	0	500		hs-cTnT:
T-T				first hour
ns-cTnT level at 1h	0	,	ng/l	
ns-cTnT level at 1 hour after initial presentation.	0	500		
Absolute change of hs-cTnT	: ng/L within th	e first hour		
et all parameters to calculate prediction	S			
And the Bottom of the Control of the				
Nodel performance: The high-sensitivity cardiac troponin T(hs	-cTnT) 0-hour/1-hour algorit	thm was reported to achieve avery	high negative predictiv	e value for acute myocardial
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve	a high positive predictive v	alue in the rule-in zone, and to be v	ery effective by triaging	IN THE CONTROL OF TH
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve resenting with suspected acute myocan	a high positive predictive v dial infarction to the ED to e	alue in the rule-in zone, and to be v ither rule-out or rule-in classificatio	ery effective by triaging ns. <sup>1,2</sup>	g approximately 75% of patients
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve	e a high positive predictive v dial infarction to the ED to e ted by Mueller <i>et al.</i> in an ex	alue in the rule-in zone, and to be v ither rule-out or rule-in classificatio cternal mulicenter cohort of 1,282 p	ery effective by triaging ns. <sup>1,2</sup> atients with a 17% rate	g approximately 75% of patients of acute myocardial infarction. <sup>3</sup>
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve resenting with suspected acute myocard n 2016, the algorithm was further validal Jse of hs-cTn assays at presentation and 9.7%); 14% as having acute myocardial i	e a high positive predictive v dial infarction to the ED to e ted by Mueller <i>et al.</i> in an ex I 1 hour later in classified 63	alue in the rule-in zone, and to be v ither rule-out or rule-in classificatio kternal mulicenter cohort of 1,282 p % of patients as having no acute m	ery effective by triaging ns. <sup>1,2</sup> ratients with a 17% rate yocardial infarction, wi	a approximately 75% of patients of acute myocardial infarction. <sup>3</sup> th a 99.1% NPV (95% CI 98.2% to
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve resenting with suspected acute myocard n 2016, the algorithm was further validal Jse of hs-cTn assays at presentation and 19.7%); 14% as having acute myocardial i esting.	e a high positive predictive v dial infarction to the ED to e ted by Mueller <i>et al.</i> in an ex I 1 hour later in classified 63	alue in the rule-in zone, and to be v ither rule-out or rule-in classificatio kternal mulicenter cohort of 1,282 p % of patients as having no acute m	ery effective by triaging ns. <sup>1,2</sup> ratients with a 17% rate yocardial infarction, wi	a approximately 75% of patients of acute myocardial infarction. <sup>3</sup> th a 99.1% NPV (95% CI 98.2% to
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve tresenting with suspected acute myocard in 2016, the algorithm was further validat lise of hs-cTn assays at presentation and 19.7%): 14% as having acute myocardial i esting.	e a high positive predictive v dial infarction to the ED to e ted by Mueller <i>et al.</i> in an ex 11 hour later in classified 63 infarction, with a PPV of 77%	alue in the rule-in zone, and to be vither rule-out or rule-in classification of 1,282 p. sternal mulicenter cohort of 1,282 p. s of patients as having no acute m. s (95% CI 70.4% to 83.0%); and 22.5	ery effective by triaging ns. <sup>1,2</sup> atients with a 17% rate yocardial infarction, wi % as having an indeten	e of acute myocardial infarction. <sup>3</sup> th a 99.1% NPV (95% CI 98.2% to minate classification after 1 hour of
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve resenting with suspected acute myocard n 2016, the algorithm was further validal Jse of hs-cTn assays at presentation and 19.7%); 14% as having acute myocardial i esting.	e a high positive predictive v dial infarction to the ED to e ted by Mueller <i>et al.</i> in an ex 11 hour later in classified 63 infarction, with a PPV of 77%	alue in the rule-in zone, and to be vither rule-out or rule-in classification of 1,282 p. sternal mulicenter cohort of 1,282 p. s of patients as having no acute m. s (95% CI 70.4% to 83.0%); and 22.5	ery effective by triaging ns. <sup>1,2</sup> atients with a 17% rate yocardial infarction, wi % as having an indeten	e of acute myocardial infarction. <sup>3</sup> th a 99.1% NPV (95% CI 98.2% to minate classification after 1 hour of
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve tresenting with suspected acute myocan in 2016, the algorithm was further validat lise of hs-cTn assays at presentation and 19.7%); 14% as having acute myocardial i esting. telated references: 1. Reichlin T, Schindler C, Drexler B, et al	e a high positive predictive vidial infarction to the ED to e ted by Mueller et al. in an exist hour later in classified 63 infarction, with a PPV of 77% I. One-hour rule-out and rul	alue in the rule-in zone, and to be wither rule-out or rule-in classification of 1,282 pm of patients as having no acute mm of 95% CI 70.4% to 83.0%); and 22.5% of patients as having no acute mm of 25% CI 70.4% to 83.0%); and 22.5% of patients as having no acute mm of acute myocardial infarction of the patients of th	ery effective by triaging ns. 1,2 atients with a 17% rate yocardial infarction, will as having an indetermination of the state of the s	g approximately 75% of patients of acute myocardial infarction.  th a 99.1% NPV (95% CI 98.2% to ninate classification after 1 hour of a patient of the control of the cont
he high-sensitivity cardiac troponin T(hs nfarction in the rule-out zone, to achieve resenting with suspected acute myocard n 2016, the algorithm was further validales of hs-cTn assays at presentation and 19.7%; 14% as having acute myocardial i esting.  **Lelated references:*  1. Reichlin T, Schindler C, Drexler B, et al. 2012;172:1211-1218.  2. Reichlin T, Twerenbold R, Wildi K, et al.	e a high positive predictive vertical infarction to the ED to extend by Mueller et al. in an extended in the ED to extend by Mueller et al. in an extended infarction, with a PPV of 77% and the ED to extended infarction, with a PPV of 77% and the ED to extended in	alue in the rule-in zone, and to be wither rule-out or rule-in classification of 1,282 pm of patients as having no acute mis (95% CI 70.4% to 83.0%); and 22.5 e-in ofacute myocardial infarction of 1-hour algorithm to rule-out and rule-out	ery effective by triaging ns. 1,2 attents with a 17% rate yocardial infarction, with a shaving an indetermant of the same high-sensitivity caule-in acute myocardial	g approximately 75% of patients of acute myocardial infarction. <sup>3</sup> th a 99.1% NPV (95% CI 98.2% to minate classification after 1 hour of rdiac troponin T. Arch Intern Med.
he high-sensitivity cardiac troponin T(hs  Ifarction in the rule-out zone, to achieve resenting with suspected acute myocard  2016, the algorithm was further validal ise of hs-cTn assays at presentation and  9,7%); 14% as having acute myocardial i esting.  elated references:  1. Reichlin T, Schindler C, Drexler B, et al  2012;172:1211-1218.  2. Reichlin T, Twerenbold R, Wildi K, et al cardiac troponin T assay. CMAJ. 2015;  3. Mueller C, Giannitsis E, Christ M, et al.	a high positive predictive vertical dial infarction to the ED to ested by Mueller et al. in an extended infarction, with a PPV of 77% infarction, with a PPV of 77% infarction, with a PPV of and rule. One-hour rule-out and rule. Prospective validation of a 187:E243-252.  Multicenter Evaluation of a 2016;68(1):76-87.e4.	alue in the rule-in zone, and to be vither rule-out or rule-in classification of 1,282 pm % of patients as having no acute mis (95% CI 70.4% to 83.0%); and 22.5 e-in ofacute myocardial infarction of 1-hour algorithm to rule-out and rule-out and rule-out.	ery effective by triaging ns. 1.2 attients with a 17% rate yocardial infarction, with 8 as having an indeterminating high-sensitivity caule-in acute myocardial I agnosis of Myocardial I	g approximately 75% of patients of acute myocardial infarction. <sup>3</sup> th a 99.1% NPV (95% CI 98.2% to minate classification after 1 hour of rdiac troponin T. Arch Intern Med.

Figure 1. An example of a model landing page.



#### A. Model title

This is the title and name of the model.

#### B. Model description

This is a short description of the model.

#### C. Research authors

These are the research authors of the paper that originally published the model.

#### D. Model tags

These are the tags that are assigned to the model. Evidencio has the following status tags: "Draft", "Public", "Private", "Under review". Evidencio has the following model type tags: "Composite model", "Sequential model", "API model". Evidencio has the following calculation method tags: "Linear model", "Logistic regression", "Cox regression", "RScript" and "Custom model". Next to this, there are tags that indicate the specialty e.g. "Cardiology".

#### E. LOT number

The LOT number indicated the model version, the model identifier, and the model publication date. Publication date is indicated as YY.MM.DD.

Additionally, the CE mark is displayed next to the LOT number. This way, medical devices can be easily recognized.

#### F. UDI number

The UDI number is an international tool that helps users identify and find information on products. UDI stands for Unique Device Identifier. Evidencio's UDIs have the following format:

(01)UDI-DI number(8012)versionnumber(4326)releasedate(240)identificationnumber

The UDI-DI number is a unique numeric code. For each medical device of Evidencio, a unique UDI-DI is ascribed. This UDI-DI is used as an "access key" for information stored in a unique device identification database (UDID). Information on Evidencio's medical devices can be found by searching for the UDI-DI number in the following data base: <a href="https://gepir.gs1.org/index.php/search-by-gtin">https://gepir.gs1.org/index.php/search-by-gtin</a>



#### G. Details button

On the top right of the model page, several clickable buttons are displayed that show a pop-up when clicked. The first button opens a pop-up concerning additional information about the model. This pop-up has three sections: Details, Study characteristics and Supporting publications & related files.

#### **Details**

The first part of the additional information concerns the details of the model as shown in Figure 2.

Additional information on the rating of a model can be found by hovering over the 'i' icon, next to the stars.



Figure 2. The model details.

#### Study characteristics

Below the 'Details section' the section labeled 'Study characteristics' provides information on the characteristics of the patient data used to derive and validate the model. Additional information is provided on the methods used to develop and/or validate the model.

An important part of the Study characteristics is the information on Supporting publications and related files. These sections can be found at the bottom of the Details-pop-up as shown in Figure 3.

Tags are attached to the different files to identify their link with the model. Examples of relevant tags are a.o.; "Peer review", "Internal validation", "External validation", and "TRIPOD". Publications that have the tags: "Internal validation" or "External validation", contain the performance characteristics of the device.

These tags are considered important, because the availability of particular information covered by the above mentioned tasks provide insight into the quality of the model development process and the model itself. As a completeness of information and quality indicator a model receives a certain number of stars when these labels can be assigned to relevant files or references.



Supporting Publicatio	ns	
Title or description		Tags
		External validation
	Internal validation	
One-Hour Rule-out and Rule-in of Acute Myocardial Infarction Using High-Sensitivity Cardiac Troponin T DOI: 10.1001/archinternmed.2012.3698		Paper
		Peer review
		Model coefficients
Related files		
Preview	Name	Tags
POF	Mueller et al, 2016.pdf	External validation
	1.05 MB	Peer review
		Paper
	Reichlin et al, 2015.pdf 289.86 kB	External validation
		Peer review
		Paper
		Model coefficients
POF	Reichlin et al, 2012.pdf	Peer review
	459.69 kB	Paper
	155155 N.D	Internal validation
		External validation
	Kaplan-Meier curves for cumulative mortality according to classification provided by the hs-cTnT 0-hour:1-hour algorithm (Mueller et al, 2016)png	
	provided by the hs-cTnT 0-hour-1-hour algorithm (Mueller et al. 2016), ppg	Figure

Figure 3. An example of Supporting publications & related files.

#### H. Intended use button

The intended use and (medical) purpose of the model can be found under the button: 'Intended use'. Among other things, the intended use indicates inclusion criteria of the medical device. Furthermore, the intended use comments on the appropriate use of the model regarding the intended use environment, intended users, and intended patient population (in- and exclusion criteria). For the ESC 0-1 Hour Algorithm the following intended use is described:

#### Intended use

The device is intended to be used by physicians to estimate the risk of 30-day acute myocardial infarction (AMI) in patients presenting with chest pain at the emergency department.

The device uses results of a Troponin I measurement at presentation and its absolute 1h change to calculate the risk of AMI within 30 days.

The device is intended to be used for patients reporting to the emergency department with chest pain, by physicians and qualified medical specialists in a clinical setting. The device is not intended for use by patients on their own.

The 0/1-Hour Algorithm is not intended to replace clinical decision-making, it can only **inform** the physician, and only provides a risk category for 30-day AMI. No direct instructions for further diagnostics, treatment, or otherwise, are given.

#### **Clinical benefit**

The 0/1-Hour Algorithm is intended to assist patients with relevant and specified clinical outcome parameters. Concretely, this is achieved by estimating a risk in order to support clinical decision making aimed at patients presenting to the emergency department with chest pain, in order to support clinical decision making regarding patient triage. Correct functioning of the 0/1-Hour Algorithm can result in these clinical benefits:

• The 0/1-Hour Algorithm can assist in risk stratification for patients.



- Risk stratification can reduce the burden of (invasive and intensive) medical procedures such as tests on patients with low risks, reducing, shortening or avoiding stays in hospitals or other care facilities.
- Risk stratification can reduce the unnecessary consumption of (scarce) medical resources, decreasing costs and increasing their availability for high risk patients.

#### Intended target population and exclusion

The ESC 0-1 Hour Algorithm is intended to be used only for a specific group of patients, corresponding to the below indications and contra-indications. The target population of the model is patients presenting to the emergency department with chest pain, provided that they fit the listed indications and contra-indications.

#### **Clinical indication**

The Calculator is intended to be used for patients presenting to the Emergency Department with Chest Pain aged 18 years or older.

#### **Contra-indications**

No contra-indications have been found.

#### User profile

Since Acute Myocardial Infarction is regarded as a 'critical healthcare situation or condition', the use of the SaMD is intended for specialised trained users. Thus, the SaMD may be used by physicians and qualified medical specialists in a clinical setting. The SaMD should not be used by patients.

#### **Intended Use Environment**

The SaMD can be used as made available on the Evidencio platform in any actively supported web-browser on personal computers, mobile devices, or tablet PCs, and on the mobile app provided by Evidencio. Furthermore, the SaMD can be used through the Evidencio iFrame representation of the SaMD, as an embedded view, provided that the specific Evidencio guidelines for iFrame implementations of this SaMD are adhered to. The model is only intended for use in settings where the usage and result of a model are never immediately needed.

#### Functioning, physical principle

The SaMD's underlying mathematical formula is a decision rule based on subtraction of the measured values of Troponin at 0 and 1 hours after presentation. The acquisition and processing of the data, the analyses to assemble the relevant criteria for the SaMD as well as the setup and refinement of the 0/1-Hour Algorithm are described in the original study from Reichlin et al. Entering the details of an individual in the Evidencio SaMD initiates the calculation of the risk of 30-day AMI and shows the absolute change of troponin and the associated risk category, i.e. rule-in, observe or rule-out for the risk of 30-day AMI.

#### I. Electronic label button

The electronic label button opens a pop-up with the location and address of Evidencio, the LOT number, the UDI number, the CE-mark, the medical device logo and a download link for the declaration of conformity of the medical device. The example of the electronic label is shown in Figure 4.



Figure 4. Example of the electronic label



#### I. Release notes

The 'Release Notes' button opens a pop-up with the latest release notes of the model. Here you can find what has changed over the last versions of the model. Additionally, if there are any known residual anomalies the user should be aware of, they are listed here.

#### K. User Manual

This user manual can be found in three places: 1) under the short description, 2) on the right of the model page, and 3) in the electronic label. Additionally, all versions of the user manual can be found in the general page for all user manuals for medical devices. The page can be found under the 'About' drop-down menu button as shown in Figure 5. The user manual page is shown in Figure 6.




Figure 5. The drop-down menu where the user manual page can be found.



Figure 6. The user manual page for all user manuals.

You (The user) can always print this downloaded manual. When necessary, you can request a paper version of the manual to be sent to you by mail. Evidencio's contact details are listed in Chapter 6 of this user manual.

#### L. Input section

The Evidencio platform allows two separate input variables; categorical, and continuous variables. For the ESC 0-1 Hour Algorithm, only the continuous variables are used.

#### Continuous variables

In the example shown in Figure 7, the **hs-cTnT level at 0h** variable, exemplifies a continuous variable.

The details for a patient can be entered by sliding the button to the correct value, or by entering the correct value in the box on the right-hand side (i.e., where the 200 is entered for **hs-cTnT level at 0h**).



Figure 7. The variable for age, where "65" has been entered.

#### Details on variable measurements

Directly underneath the name for each variable, additional details can be provided on the methods required to enter the correct value for each variable. In Figure 8, the details below **hs-cTnT level at 0h** explain what the risk factors are.



Figure 8. An example on how additional information can be provided for a variable.

#### M. Result section

At the bottom of the page, the results of the model are shown.

#### Result calculation

When all variables are filled in, a result will be calculated. No risk is displayed until all variables are filled in. The result section indicates "Set all parameters to calculate prediction."

#### Result interpretation

In the result interpretation, a risk stratification is given based on the risk score. Furthermore, some explanation about the model is given. An example of the information is shown In Figure 9.




Figure 9. The result information



#### Relevant information for correct use of the model

At the bottom of the page, there is a link to Evidencio's terms and conditions of use, the privacy policy, and the disclaimer.

### 5. Use of Medical devices

In general, and unless explicitly stated otherwise, CE-marked tools on Evidencio are only to be used by physicians in a clinical setting, and are not for patient use.

To use the tool, Evidencio requires a stable internet connection and runs on the following devices:

- Personal computers or laptops using the following browsers:
  - Safari (the latest three versions)
  - o Chrome (the latest three versions)
  - Firefox (the latest three versions)
  - Edge (the latest three versions)
- Tablets or smartphones running on the next operating systems:
  - IOS (the latest three versions)
  - Android (the latest three versions)

The medical device cannot be used in combination with Internet Explorer. The personal computers, laptops, tablets or smartphones used should at least be able to have an internet connection and use the browsers mentioned above. The minimal screen resolution should be 800x600.

Furthermore, the model may be used through the Evidencio iFrame representation of the calculator, as an embedded view, provided that the specific Evidencio guidelines for iFrame implementations of that model are adhered to.

The Evidencio SaMD models can be used with any browser settings that don't distort the regular display of websites, with a 50% to 500% zoom rate, and at a display resolution starting from 800x600. However, factory recommended browser settings, 100% zoom rate and regular display resolution are recommended.

This model is only intended for use in settings where the usage and result of a model are never immediately needed.

# 6. Manufacturer details

Any serious incident that has occurred in relation to the device should be reported to the manufacturer and the competent authority of the country in which you, the reader, are established. A competent authority is the institute that governs all issues related to medical devices in a country.

Contact details of your competent authority can be found here: <a href="https://www.ema.europa.eu/en/partners-networks/eu-partners/eu-member-states/national-competent-authorities-human">https://www.ema.europa.eu/en/partners-networks/eu-partners-networks/eu-partners/eu-member-states/national-competent-authorities-human</a>

Please contact Evidencio when you suspect any malfunction or changes in the performance of a medical device. Do not use the device, until Evidencio replies to your message that it is safe to start using it again.

Contact details of Evidencio:



Evidencio B.V., Irenesingel 19, 7481 GJ Haaksbergen, The Netherlands www.evidencio.com

tel: +31 53 85195 08

e-mail: info@evidencio.com